


Cedars-Sinai Department of Neurosurgery

# 2011 NANOMEDICINE AND DRUG DELIVERY RESEARCH CONFERENCE

*For Scientific and Healthcare Professionals*




**MARCH 4-5  
2011**



**CEDARS-SINAI**  
DEPARTMENT OF NEUROSURGERY

**Cedars-Sinai Medical Center  
Harvey Morse Auditorium**  
Plaza Level, South Tower  
8700 Beverly Boulevard  
Los Angeles, CA 90048



For further information  
please call the  
**Department of  
Neurosurgery**  
at 310-423-9522

# AGENDA

## FRIDAY, MARCH 4, 2011


7:30am to 8:15am	<b>Registration and Continental Breakfast</b>	
8:15am to 8:20am	Welcome and Introduction	Julia Y. Ljubimova, MD, PhD
8:20am to 8:30am		Steven Piantadosi, MD, PhD
8:30am to 9:00am	Nanotechnology-based Cancer Therapeutics: View from the NCI Alliance for Nanotechnology in Cancer	Piotr Grodzinski, PhD
9:00am to 9:45am	Multifunctional Nanopreparations for Cancer	Vladimir P. Torchilin, PhD
9:45am to 10:00am	<b>BREAK</b>	
10:00am to 10:45am	Nanomedicine for Brain Cancer with Blood-Brain Barrier Molecular Trojan Horses	William Pardridge, MD
10:45am to 11:45am	<b>KEYNOTE SPEAKER:</b> Synthetic Molecules and Nanoparticles to Image Tumors, Atherosclerosis, and Nerves	Roger Tsien, PhD
11:45am to 12:45pm	<b>LUNCH</b>	
12:45pm to 1:30pm	Brain Microchips to Treat Brain Tumors	Henry Brem, MD
1:30pm to 2:15pm	Drug Delivery to the Brain (with Emphasis on Iron Oxide Nanoparticles)	Edward A. Neuwelt, MD
2:15pm to 3:00pm	Role of Pattern Recognition Receptor Signaling in Brain Cancer Biology and the Development of Novel Therapeutics	Maria Castro, PhD
3:00pm to 3:15pm	<b>BREAK</b>	
3:15pm to 4:00pm	Nanotechnology for Cancer Therapy: Lessons Learned from NCI's Nanotechnology Characterization Lab	Scott E. McNeil, PhD
4:00pm to 5:00pm	<b>PANEL DISCUSSION:</b> Government and Private Sector Roles in Nanomedicine Development	Piotr Grodzinski, PhD Kathryn Koeller, PhD Lon Nelson, Director Market Strategy Maurizio Vecchione, CEO Jason L. Yovandich, PhD
5:00pm to 6:00pm	<b>POSTER SESSION</b>	
6:00pm	<b>ADJOURN</b>	

## SATURDAY, MARCH 5, 2011

7:30am to 8:25am	<b>Registration and Continental Breakfast</b>	
8:25am to 8:30am	Overview	Julia Y. Ljubimova, MD, PhD
8:30am to 9:15am	A Novel Nanopolymer to Inhibit Angiogenesis and Increase the Anti-Tumor Immunity	Manuel Penichet, MD, PhD

AGENDA CONTINUED ON NEXT PAGE


# AGENDA



## SATURDAY, MARCH 5, 2011

9:15am to 10:00am	Biomaterials and Drug Delivery: State-of-the-Art and Future Prospects	Jindrich H. Kopecek, PhD, DSc
10:00am to 10:15am	<b>BREAK</b>	
10:15am to 11:00am	Development of RNAi Therapeutics for CNS Diseases	Dinah Sah, PhD
11:00am to 11:45am	Lipid-based Formulations for RNAi-based Therapeutics	Paul A. Burke, PhD
11:45am to 12:30pm	<b>LUNCH</b>	
12:30pm to 1:00pm	Tumor-Targeted Nanoparticles Derived from Viral Capsid Protein	Lali K. Medina-Kauwe, PhD
1:00pm to 1:45pm	Novel Nanomedicine Approaches for Protein Delivery to the Brain	Alexander Kabanov, PhD
1:45pm to 2:30pm	Summary of Nanomedicine Drug Delivery and Treatment	Keith L. Black, MD
2:30pm-2:45pm	<b>CLOSING</b>	Keith L. Black, MD Julia Y. Ljubimova, MD, PhD

# FACULTY



## CEDARS-SINAI MEDICAL CENTER FACULTY

### COURSE CO-DIRECTORS

#### **Keith L. Black, MD**

Professor and Chairman, Department of Neurosurgery  
Director, Maxine Dunitz Neurosurgical Institute  
Director, Johnnie L. Cochran Comprehensive Cancer Center  
Ruth and Lawrence Chair in Neuroscience

#### **Julia Y. Ljubimova, MD, PhD**

Professor of Neurosurgery  
Director of Drug Delivery and Nanomedicine  
Department of Neurosurgery

#### **Eggehard Holler, PhD, Prof Dr**

Research Scientist  
Department of Neurosurgery

### CSMC FACULTY

#### **Maria Castro, MD**

Professor of Medicine and Biomedical Sciences  
Co-Director, Gene Therapeutics Research Institute  
Cedars-Sinai Medical Center  
Professor, Molecular and Medical Pharmacology/UCLA

#### **Lali K. Medina-Kauwe, PhD**

Associate Professor, Dept. of Biomedical Sciences Cedars-Sinai Medical Center  
Associate Professor, UCLA Geffen School of Medicine

#### **Steven Piantadosi, MD, PhD**

Phase One Foundation Chair  
Director, Samuel Oschin Comprehensive Cancer Institute

FACULTY CONTINUED ON NEXT PAGE

# FACULTY

## GUEST FACULTY

### **Henry Brem, MD**

Harvey Cushing Professor and Chairman,  
Department of Neurosurgery  
Professor of Neurosurgery, Oncology, and Ophthalmology  
Neurosurgeon-in-Chief  
The Johns Hopkins School of Medicine  
Baltimore, MD

### **Paul A. Burke, MD**

Chief Technology Officer  
Oligonucleotide Therapeutics Unit at Pfizer  
Cambridge, MA

### **Piotr Grodzinski, PhD**

Director, Nanotechnology for Cancer Programs  
National Cancer Institute  
Bethesda, MD

### **Alexander Kabanov, PhD**

Director, Center for Drug Delivery and Nanomedicine  
University of Nebraska Medical Center  
Omaha, NE

### **Kathryn Koeller, PhD**

Scientific Review Officer  
Biological Chemistry and Macromolecular Biophysics  
Synthetic and Biological Chemistry B  
Division of Basic and Integrative Biological Sciences  
National Institutes of Health  
Bethesda, MD

### **Jindrich H. Kopecek, PhD, DSc**

Distinguished Professor of Bioengineering  
Distinguished Professor of Pharmaceutics and  
Pharmaceutical Chemistry  
Center for Controlled Chemical Delivery  
University of Utah  
Salt Lake City, UT

### **Lon Nelson**

Director of Market Strategy - Life Science & Industry  
Leica Microsystems, Inc.  
Chicago, IL

### **Scott E. McNeil, PhD**

Director, Nanotechnology Characterization Laboratory  
Director, Imaging and Nanotechnology Group  
National Cancer Institute at Frederick  
Frederick, MD

### **Edward A. Neuwelt, MD**

Professor, Departments of Neurology and Neurosurgery  
Director, Blood Brain Barrier Program  
Oregon Health Sciences University  
Portland, OR

### **William Pardridge, MD**

Professor, Department of Medicine  
David Geffen School of Medicine at UCLA  
Los Angeles, CA

### **Manuel Penichet, MD, PhD**

Associate Professor of Surgery, Microbiology,  
Immunology, and Molecular Genetics  
Division of Surgical Oncology  
Department of Surgery  
David Geffen School of Medicine at UCLA  
Los Angeles, CA

### **Dinah Sah, PhD**

Vice President, Research, CNS, and Oncology  
Alnylam Pharmaceuticals  
Cambridge, MA

### **Vladimir P. Torchilin, PhD, DSC**

Distinguished Professor and Director  
Center for Pharmaceutical Biotechnology and Nanomedicine  
Northeastern University  
Boston, MA

### **Roger Tsien, PhD - Keynote Speaker**

Investigator, Howard Hughes Medical Institute  
Professor, Department of Pharmacology  
Professor, Department of Chemistry and Biochemistry  
University of California, San Diego School of Medicine  
La Jolla, CA

### **Maurizio Vecchione, CEO**

Arrogene Nanotechnology, Inc.  
Los Angeles, CA

### **Jason L. Yovandich, PhD**

Program Director, Biological Resources Branch  
National Cancer Institute at Frederick  
Frederick, MD

## COURSE DESCRIPTION

The conference is aimed at bringing together a multi-disciplinary group of top national academic researchers, clinicians, NIH / NCI and private industry for a compelling discussion on identified issues and emerging aspects in the treatment of cancers using nanomedicine drugs and technology.

The lectures will demonstrate advances in nanotechnology and nanomedicine, polymer- and lipid-based carriers, antibody-drug conjugates, molecular imaging, and drug delivery platforms to treat cancer. The program will offer participants an opportunity to engage in interactive discussions with renowned faculty.


## REGISTRATION INFORMATION


### Pre-registration for the conference is required.

This conference is provided to scientific and healthcare professionals at no charge, and includes lunch and parking. Space is limited.

To register, please call (310) 423-9522 or go to <http://www.cedars-sinai.edu/neuroconferences>

We encourage participation by all individuals.

 If you have a disability, advance notification of any special needs will help us better serve you.



## ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

Commercial support for this educational activity is pending and will be acknowledged at the conference.